Outlook Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Outlook Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-54.4%

Buyback Yield

Total Shareholder Yield	-54.4%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Nov 03

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Aug 30

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Aug 10

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Jul 06

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Jul 05

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if OTLK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OTLK's dividend payments have been increasing.

Dividend Yield vs Market

Outlook Therapeutics Dividend Yield vs Market

How does OTLK dividend yield compare to the market?
Segment	Dividend Yield
Company (OTLK)	n/a
Market Bottom 25% (US)	1.3%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.3%
Analyst forecast (OTLK) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate OTLK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OTLK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate OTLK's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OTLK has not reported any payouts.

Outlook Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

New major risk - Share price stability

Price target decreased by 9.5% to US$33.60

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Forecast to breakeven in 2027

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

New major risk - Financial position

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Insufficient new directors

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Price target decreased by 13% to US$38.50

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

New major risk - Share price stability

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

Price target decreased by 11% to US$2.01

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Consensus revenue estimates decrease by 92%, EPS upgraded

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates decrease by 33%

Price target decreased by 61% to US$2.63

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Consensus EPS estimates fall by 12%

New major risk - Negative shareholders equity

Consensus EPS estimates upgraded to US$0.21 loss

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Price target decreased by 7.3% to US$6.13

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Price target decreased by 9.5% to US$6.33

High number of new directors

Chief Commercial Officer recently sold US$204k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Consensus forecasts updated

Forecast breakeven date moved forward to 2024

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Forecast breakeven date pushed back to 2025

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Independent Director recently bought US$111k worth of stock

Price target increased to US$7.25

No longer forecast to breakeven

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Price target decreased to US$6.33

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics: A One-Buck Lottery Ticket

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Price target decreased to US$6.58

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought US$257k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics: Likely FDA Approval, Possible Buyout